Biological Markers and Prognosis in Thyroid Cancer
Author Information
Author(s): Hajjar Rami, Duta Ciprian, Faur Ionut Flaviu, Prodan-Barbulescu Catalin, Alhajjar Hadi, Pantea Stelian
Primary Institution: Victor Babeș University of Medicine and Pharmacy Timișoara
Hypothesis
This study examines the relationship between biological markers—BRAF V600E mutation, thyroglobulin (Tg), and calcitonin—and thyroid cancer prognosis.
Conclusion
The BRAF V600E mutation is associated with more aggressive thyroid cancer and poorer outcomes, while Tg and calcitonin are reliable prognostic markers.
Supporting Evidence
- Patients with the BRAF V600E mutation were older and presented with advanced stages.
- Lower biomarker levels were associated with significantly better five-year survival rates.
- Advanced stage, age, and elevated biomarkers independently predicted increased mortality risk.
Takeaway
This study found that certain markers in thyroid cancer can help doctors understand how serious the cancer is and how to treat it better.
Methodology
This retrospective study analyzed 395 thyroid cancer patients treated from 2010 to 2018, measuring preoperative Tg and calcitonin levels and analyzing survival rates using Kaplan–Meier and Cox regression.
Potential Biases
Potential biases due to incomplete data from medical records and uncontrolled confounding factors.
Limitations
The study's retrospective design may introduce biases, and it was conducted in a single medical center, which may limit generalizability.
Participant Demographics
The study included 395 thyroid cancer patients, with a higher prevalence of women and a mean age of 54.2 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website